Benitec Biopharma Inc. BNTC
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Benitec Biopharma Inc. (BNTC) is a healthcare company listed in the US with a market value of about $315M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -491%.
About Benitec Biopharma
Benitec Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $12M in 2019 to $75000 in 2023, a decline of about 72.0% a year. It was profitable in 1 of the last 8 years in our data. Its share count rose by 3260% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $75000 | $73000 | $59000 | $102000 | $12M |
| Net income | -$46M | -$38M | -$22M | -$20M | -$18M | -$14M | -$8M | $3M |
| Free cash flow | -$17M | -$24M | -$20M | -$18M | -$16M | -$13M | -$8M | $4M |
| EPS (diluted) | $-0.98 | $-1.05 | $-1.22 | $-14.12 | $-37.88 | $-54.91 | $-137.70 | $51.85 |
| Net margin | — | — | — | -26082.7% | -24942.5% | -23528.8% | -8111.8% | 21.4% |
| ROIC | -22.8% | -33.6% | -37.4% | -1980.8% | -381.9% | -53.1% | -61.5% | 12.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $23.32, 158% above the current price; targets range from $17.00 to $32.00; the consensus rating is “Strong buy”; expected EPS is $-1.19 for the fiscal year ending June 30, 2027.
Frequently asked questions
Does Benitec Biopharma pay a dividend?
Not currently.
Is Benitec Biopharma a good stock to buy?
We do not give buy or sell advice. Benitec Biopharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.